Numab is a biotechnology company developing multi-specific antibody-based immunotherapies for inflammation and cancer. They use proprietary platforms λ-Cap™ and MATCH™ to overcome historical drug discovery barriers and build a pipeline of new and important medicines.

Numab Therapeutics is developing multi-specific antibody-based immunotherapies for inflammation and cancer. Reproducible plug-and-play therapeutic design process using proprietary platforms λ-Cap™ and MATCH™ puts Numab in a unique position to overcome historical drug discovery barriers and build a pipeline of first-in-class and best-in-class medicines aimed to maximize patient benefits. 

Our lead candidate NM26, a unique multi-specific targeting IL-4/13 and IL-31 for best-in-class efficacy, is developed with a vision of delivering a lifelong cure to patients suffering from atopic dermatitis (AD) and other potential indications.


3sbio

Eisai

HBM Healthcare Investments AG

RTW Investments

Biotechnology Value Fund

BlackRock

Novo Holdings

Octagon Capital Advisors

Cormorant Asset Management

Forbion Capital Partners

HBM Partners

BVF Partners

Numab Therapeutics AG

We are excited to announce today that Numab and ONO PHARMACEUTICAL CO., LTD. entered a global research, development and commercialization collaboration for NM49, a multi-specific antibody designed to activate tumor associated macrophage phagocytosis for the treatment of cancers, identified through Numab’s proprietary discovery and engineering technology platform.
 
This collaboration with a leading pharma company further validates Numab’s unique plug-and-play antibody technology platform and demonstrates its ability to continue to generate exciting candidates for the treatment of cancer and inflammatory diseases.
 
To learn more, please read our press release: 
https://lnkd.in/dfsii_J3 

We are excited to announce today that the first patient has been dosed in the multiple ascending dose (MAD) study of the Phase 1a/b clinical trial of NM26 for the treatment of moderate-to-severe atopic dermatitis #atopicdermatitis (AD). The MAD study in AD patients is a planned continuation of the Company’s ongoing single ascending dose (SAD) portion of the Phase 1a/b trial in healthy volunteers, being conducted in collaboration with Asia-regional partner Kaken Pharmaceutical. 
 
NM26 inhibits three key pathways involved in the pathophysiology of AD. While standard of care blocks IL-4 and IL-13 to reduce inflammation, NM26-2198 also blocks IL-31, thereby targeting an additional independent pathway that contributes to inflammation and itch. We believe that NM26 has the potential to deliver faster relief from itch and more pronounced improvement of skin lesions, providing a more effective therapeutic option for patients. 
 
To learn more, read our press release: https://lnkd.in/eGbzKtrT
 
#FirstPatient #ClinicalTrials #Inflammation 

Congratulations to our partner Tillotts for the successful spin-out of Mage Biologics, which is advancing an anti-TNF therapeutic antibody – discovered at Numab in collaboration with Tillotts – as an innovative oral therapy for Ulcerative Colitis. Read the full press release here: https://bit.ly/43Jmbyw

Today, we are thrilled to announce that the first subject has been dosed in our Phase 1a/1b clinical study in collaboration with our partner Kaken Pharmaceutical. The study evaluates NM26-2198, a novel bi-specific antibody targeting the neuroimmune axis in #atopicdermatitis (AD). 

NM26-2198 inhibits three key pathways involved in the pathogenesis of AD; while standard of care blocks IL-4 and IL-13 to reduce inflammation, NM26-2198 also blocks IL-31, thereby specifically targeting the neuroinflammatory pathway that causes itch. By simultaneously inhibiting itch and inflammation, NM26-2198 has the potential to improve quality of life relative to current standard of care treatments.

To learn more, read our press release: https://bit.ly/3pEo1SR

COM:NUMAB

Numab

Analysis Not Available